NCT05322980

Brief Summary

This is a retrospective single-center cohort study. The comparison in short- and long-term outcomes will be made between those with and without primary microcephaly in infants weighing ≤ 500 g.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
22

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Apr 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 4, 2022

Completed
1 month until next milestone

Study Start

First participant enrolled

April 5, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 12, 2022

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

November 20, 2024

Status Verified

November 1, 2024

Enrollment Period

9 months

First QC Date

March 4, 2022

Last Update Submit

November 18, 2024

Conditions

Keywords

500 grams or lessprognosis

Outcome Measures

Primary Outcomes (1)

  • Rate of neurodevelopmental impairment

    Having at least one of the following conditions: cognitive impairment, cerebral palsy, visual impairment, or hearing impairment. Cognitive impairment was defined as a modified DQ score of ≤ 70 using the Kyoto Scale of Psychological Development. CP was defined as (1) a non-progressive disorder of the central nervous system appearing in the early years of life and clinically characterized by a persistent but not unchanging impairment of movement and posture and/or (2) the Gross Motor Function Classification System level ≥ II. Visual impairment was defined as unilateral or bilateral blindness, or any other condition requiring corrective lenses, which were diagnosed or determined by ophthalmologists. Hearing impairment was defined as unilateral or bilateral hearing loss that requires a hearing aid. The diagnosis of hearing loss was made by otolaryngologists using auditory steady-state response.

    3 years of age

Secondary Outcomes (27)

  • Survival rate

    At discharge from neonatal intensive care unit, an average at 40 weeks' postmenstrual age.

  • Rate of severe bronchopulmonary dysplasia

    At 36 weeks' postmenstrual age

  • Rate of need for surgery for patent ductus arteriosus

    In neonatal intensive care unit, an average of up to 4 weeks of life

  • Rate of severe intraventricular hemorrhage

    In neonatal intensive care unit, an average of up to 2 weeks of life

  • Rate of periventricular leukomalacia

    In neonatal intensive care unit, an average of up to 40 weeks' postmenstrual age

  • +22 more secondary outcomes

Study Arms (2)

Microcephaly

Infants with primary microcephaly.

Diagnostic Test: Microcephaly

Control

Infants without primary microcephaly.

Interventions

MicrocephalyDIAGNOSTIC_TEST

Those with a z score of birth head circumference \< -2 (primary microcephaly) are classified into the Microcephaly group.

Microcephaly

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Those who were admitted to Nagano Children's Hospital NICU between January 1, 2010, and December 31, 2019.

You may qualify if:

  • Live-born infants weighing ≤ 500 g at birth
  • Infants whose clinical course is available in the electronic medical record

You may not qualify if:

  • Stillbirths
  • Infants who received only palliative care at birth
  • Outborn infants
  • Infants whose assessment at 3 years of age not completed at data analysis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nagano Children's Hospital

Azumino, Nagano, 399-8288, Japan

Location

MeSH Terms

Conditions

Microcephaly

Condition Hierarchy (Ancestors)

Craniofacial AbnormalitiesMusculoskeletal AbnormalitiesMusculoskeletal DiseasesMalformations of Cortical Development, Group IMalformations of Cortical DevelopmentNervous System MalformationsNervous System DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Ryo Itoshima, MD

    Nagano Children's Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Researcher

Study Record Dates

First Submitted

March 4, 2022

First Posted

April 12, 2022

Study Start

April 5, 2022

Primary Completion

December 31, 2022

Study Completion

December 31, 2022

Last Updated

November 20, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share

Locations